CHAPTER 2

Starch Functionalized Magnetite Nanoparticles: A Green, Biocatalyst for One-pot Multicomponent Synthesis of Imidazopyrimidine Derivatives in Aqueous Medium under Ultrasound Irradiation

Starch Functionalized Magnetite Nanoparticles: A Green, Biocatalyst for One-pot Multicomponent Synthesis of Imidazopyrimidine Derivatives in Aqueous Medium under Ultrasound Irradiation

2.1 Introduction

Nitrogen-containing heterocyclic moieties get much more attention due to its biological, agrochemical and pharmaceutical properties. Imidazopyrimidines, which have two nitrogen-containing heterocyclic imidazole and pyrimidine core units, possess several biological activities (Wahe et al. 2003) like antioxidant, antibiotic, antiarrhythmic, antiinflammatory, antiviral, antimicrobial, anti-diabetic, herbicidal, anti-cancer (Klutchko et al. 1998), calcium anagostic (Alajarin et al. 1994), antineoplastic (Badawey et al. 1995), antihepatitis B and as well as DNA-gyrase inhibitors and lipid peroxidation inhibitor properties (Le Corre et al. 2010, Neochoritis et al. 2011).

Several methods have been reported for the synthesis of imidazopyrimidine derivatives under different conditions and diverse catalysts like L-proline (Kalita et al. 2016), citric acid (Warekar et al. 2016), silica sulfuric acid (Wu et al. 2010), sulfamic acid (Yao et al. 2008), boric acid (Meshram et al. 2012), MgO (Sheibani et al. 2013), [PVPH]ClO⁴ (Abedini et al. 2016), ZnClO⁴ (Kaur et al. 2015), *P*-TSA (Reddy et al. 2014), $NH₄OH$ (Hu et al. 2012), $H₃PO₄-Al₂O₃$ (Shaterian et al. 2014), RHA [pmim]HSO₄ (Shirini et al. 2016), Fe₃O₄@IM (Hemmati et al. 2016), [bmim][BF₄] (Yao et al. 2010).

However these procedures suffer from comparatively harsh reaction conditions, longer reaction time, low yields and use of volatile organic solvents. Therefore, the development of an energy and environment efficient greener protocol for the synthesis of these heterocyclic compounds is always in demand.

In the last few decades, the construction of biologically active complex structures in a single step by multicomponent synthesis is one of the most promising areas of green chemistry. Successful implementation of this single step approach allows high atom economy, reduces reaction time, low cost due to lesser material consumption as compared to multi-step synthesis. However, limited methods have been reported for the synthesis of imidazopyrimidine derivatives via one pot. Imidazopyrimidines could be synthesized via multicomponent reaction (MCR) it reduces processing time, cost and waste materials. Another aspect of such green synthesis is the requirement of an alternative solvent like water (Khazaei et al. 2015, Rajarathinam et al. 2016, Komykhov et al. 2016, Tamaddon et al. 2014) supercritical $CO₂$, ethylene glycol (Survase et al. 2017, Nagarapu et al. 2013), ionic liquids (Velasco et al. 2015, Zhao et al. 2003), glycerol (Singh et al. 2016, Radatz et al. 2011) etc. which can be used instead of conventional volatile organic solvents. Among these, water is sustainable, non-toxic, inexpensive and can dissolve a variety of organic and inorganic compounds. In this respect, water has attracted much attention due to advantages in term of economic, ecological and environmental point of view. Since green synthesis procedures have generally been found to be relatively slower; therefore, workers have often resorted to strong ultrasound irradiation (>20 Hz) for smooth conduct of the reaction. Ultrasound radiation brings physical and chemical changes due to the formation and destruction of cavitation space in the reaction mixture. Ultrasonic radiations are useful for all type of catalysts but are most effective for the catalysts which are intertwined or magnetic because ultrasound radiation helps to disperse the catalyst particulates in the reaction mixture equally (Zou et al. 2012, Tabassum et al. 2015, Cappelletti et al. 2015, Banerjee 2017, Noori et al. 2017).

Higher efficiency of green synthesis protocols for multicomponent synthesis can be achieved by using an appropriate nanocatalyst. Nowadays enzymes and biomolecules functionalized nanoparticles are being used extensively in organic synthesis as well as in biomedical sciences (Gupta et al. 2015, Gawande et al. 2012, Maleki et al. 2014, Subbiah et al. 2010, Mout et al. 2012). Functionalized nanocatalysts display improved stability against aggregation, thereby giving access to higher surface area and more catalytically active sites. Additionally, functionalization also influences the properties of active sites on the nanocatalyst (Singh et al. 2016). Because of this; the present investigation utilizes starch functionalized superparamagnetic magnetite nanoparticles for multicomponent synthesis of imidazopyridine derivatives. Starch is an excellent substrate for supporting the nanoparticles because it contains hydroxyl groups which stabilize the nanoparticles. Besides this, starch is an economical and biodegradable natural polymer of glucose. Utilization of such natural molecules for the functionalization of heterogeneous catalysts is

one of the most important thrust areas in green chemistry. To the best of our knowledge, the catalytic activity of starch functionalized magnetite nanoparticles for the one-pot multicomponent synthesis of imidazopyrimidine derivatives in aqueous medium under ultrasound irradiations has not been reported till date.

Scheme 2.1 *s*-Fe₃O₄ catalyzed synthesis of imidazopyrimidines

Moreover, superparamagnetic nanoparticles can be easily separated by placing magnet below the reaction vessel. The nanoparticles can then be reused by re-dispersing them again in fresh reaction medium after removal of the magnetic field. Thus, a new dimension in organic synthesis for the devolvement of more efficient and green methodology for the synthesis of imidazopyridine derivatives (4) **(Scheme 2.1)** is achieved.

2.2 Results and Discussion

2.2.1 Nano-catalyst characterization

The starch functionalized superparamagnetic nanoparticles *s*-Fe3O⁴ were synthesized by co-precipitation method as reported by Prakash et al. and characterized by using different analytical and spectroscopic techniques (Singh et al. 2016). How starch was attached to the magnetite nanoparticles was investigated by FT-IR spectroscopy. The FT-IR spectrum of pure soluble starch shows characteristic peaks at $1,155$ cm⁻¹ for the stretching frequency of glycosidic C-O-C and $1,023$ cm⁻¹ for C-O bonds another peak, due to O-H stretching mode of starch, is observed at 3412 cm^{-1} . In contrast to this, the FT-IR of *s*-Fe3O⁴ displays the stretching frequencies of the C-O-C and C-O bonds at 1,150 and 1,025 cm^{-1} respectively and appearance of an intense peak at 584 cm^{-1} is due to the stretching frequency of Fe-O bond supports the formation of s -Fe₃O₄ (**Figure 2.1**).

Figure 2.1 FT-IR of s -Fe₃O₄

The XRD diffraction spectrum of s -Fe₃O₄ is shown in **Figure 2.2**. The indexed planes (220) , (311) , (400) , (422) , (511) , and (440) agree very well with the magnetite phase as per JCPDS card no-89-0688. The absence of any other peak indicates that only pure magnetite phase nanoparticles have been formed. Moreover, starch functionalization does not impact the XRD pattern of the magnetite phase. The SEM analysis of s -Fe₃O₄ was performed to investigate the effect of starch on magnetite particle morphology (**Figure 2.3**). The SEM image clearly shows the homogenous morphology and small particle size of *s*-Fe3O4. The presence of C, along with Fe and O in the Energy Dispersive X-Ray Analysis (EDAX), reaffirms the attachment of starch to magnetite (**Figure 2.4**). The TEM images s -Fe₃O₄ is spherical in nature and very fine particles in the case of s -Fe₃O₄ shows nano Fe3O⁴ are functionalized with starch (**Figure 2.5**).

Figure 2.2 XRD pattern of *s*-Fe₃O₄

Figure 2.3 SEM image of *s*-Fe₃O₄ **Figure 2.4** EDAX of *s*-Fe₃O₄.

Figure 2.5 TEM image *s*-Fe₃O₄

Figure 2.6 MPMS analysis; Magnetic moment versus magnetic field graph of Fe₃O₄ and *s*-Fe3O4

The magnetic properties of the starch functionalized magnetite nanoparticles were analyzed by Mission Planning and Monitoring System (MPMS) **Figure 2.6** shows the magnetization curve of s -Fe₃O₄. The absence of hysteresis loop shows that s -Fe₃O₄ is superparamagnetic. Furthermore, the magnetic moment of s -Fe₃O₄ (51.9 emu/g) is lower than Fe₃O₄ (71.3 emu/g) due to starch functionalization.

2.2.2 Optimization of Reaction Conditions

To establish the optimized conditions benzaldehyde (**1a**), malononitrile (**2a**) and 2-aminobenzimidazole (**3**) in (1.2: 1.2: 1 molar ratio) was chosen as a model reaction for the synthesis of imidazopyrimidine (**4a**).

The model reaction was carried out in reflux and ultrasound irradiation method to compare the effectiveness of this methodology. When model reaction was done under reflux, the reaction was completed in 2h and gave 80% yield of the product. While in ultrasound irradiation method it gave 98% of the product in 3 min because catalyst s -Fe₃O₄ was homogenized in reaction mixture by ultrasound irradiation so all other optimization was carried out by ultrasound method. To find a suitable solvent the model reaction was carried out with 5 mg of s -Fe₃O₄ in various solvents at room temperature under ultrasound irradiation. In non-polar solvents such as xylene, toluene, benzene no product was obtained after 1h (**Table 2.1, entries 1-3**). Polar-aprotic solvents such as 1,4-dioxane, acetonitrile, dichloromethane gave the imidazopyrimidine (**4a**) in 25-40% yield after one hour (**Table 2.1, entries 4-6**). In the case of polar- protic solvents like methanol, ethanol, and water

gave the product (**4a**) in 40-98% yield (**Table 2.1, entries 7-9**). The best result was obtained in water almost complete conversion of the reactants into the product (**4a**) was achieved with an isolated yield of 98% in 3 minutes (**Table 2.1, entry 9**). To understand the effectiveness of s -Fe₃O₄ nano catalyst in the synthesis of imidazopyrimidines some controlled experiments have been done with the model reaction under the same reaction conditions. The model reaction mixture was irradiated under ultrasound without catalyst s -Fe₃O₄ in water at r.t. However, there was no formation of 2-amino-4-phenyl-1,4dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitrile (**4a**) in 1h (**Table 2.1, entry 10**). In another controlled experiment, the reaction was also performed in the presence of starch only (no s -Fe₃O₄) but no product was formed in this case. The reaction was attempted with nano $Fe₃O₄$ (without starch functionalization) separately again, in this case, only 30% of the product was obtained under the same reaction conditions (**Table 2.1, entry 11, 12**).

Furthermore, optimization of catalyst loading was investigated with catalyst concentration 2, 3 and 4 mg gave 50%, 80%, and 98% yields of the desired product respectively (**Table 2.1, entries 13–15**), the results show that 4 mg of s -Fe₃O₄ was optimal and excessive amount of catalyst did not increase the rate and yield of the product. The product (**4a**) was characterized by spectral data $(\text{IR}, {}^{1}\text{H}, {}^{13}\text{C} \text{ NMR})$ and confirmed by comparing with the reported.

Table 2.1 Evaluation of solvents and amount of the catalyst for the synthesis of 4a^a

^a Reaction conditions: Benzaldehyde 1a (1.2 mmol), malononitrile 2a (1.2 mmol) and 2-aminobenzimidazole $3(1.0 \text{ mmol})$ in the presence of s -Fe₃O₄ at room temperature under ultrasound irradiation, ^bIsolated yield.

2.2.3 Substrate Scope

With optimized conditions in hand (**Table 1, entry 13**), the scope of this s -Fe₃O₄ catalyzed protocol was investigated with a variety of aromatic aldehydes such as benzaldehyde (**1a**), 2-methylbenzaldehyde (**1b**), 4-methoxybenzaldehyde (**1c**), 2-naphthaldehyde (**1d**), 2-nitrobenzaldehyde (**1e**), 4-nitrobenzaldehyde (**1f**), 2-chlorobenzaldehyde (**1g**), 3-chlorobenzaldehyde (**1h**), 4-chlorobenzaldehyde (**1i**), 2,3 dichlorobenzaldehyde (**1j**), 4-fluorobenzaldehyde (**1k**), 4-bromobenzaldehyde (**1l**) and malononirile (**2a**) with 2-aminobenzimidazole (**3**) which leads to a series of imidazopyrimidine derivatives viz. 2-amino-4-phenyl-1,4-dihydrobenzo[4,5]imidazo[1,2 a]pyrimidine-3-carbonitrile (**4a**), 2-Amino-4-(o-tolyl)-1,4-dihydrobenzo[4,5]imidazolo[1,2 a]pyrimidine-3-carbonitrile (**4b**), 2-amino-4-(4-methoxyphenyl)-1,4 dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3 carbonitrile (**4c**), 2-amino-4-(naphthalen-1 yl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitrile (**4d**), 2-amino-4-(2 nitrophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitrile **(4e)**, 2-amino-4-(4-nitrophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitrile **(4f)**, 2-amino-4-(2-chlorophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitrile **(4g),** 2-amino-4-(3-chlorophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-

Chapter 2

carbonitrile (4h), 2-amino-4-(4-chlorophenyl)-1,4-dihydrobenzo^{[4},5]imidazolo^{[1},2a]pyrimidine-3-carbonitrile **(4i)**, 2-amino-4-(2,3-dichlorophenyl)-1,4 dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitrile **(4j)**, 2-Amino-4-(4 fluorophenyl)-1,4-dihydrobenzo[4,5]imidazolo[1,2-a]pyrimidine-3-carbonitrile **(4k),** 2-Amino-4-(4-bromophenyl)-1,4-dihydrobenzo[4,5]imidazolo[1,2-a]pyrimidine-3 carbonitrile **(4l)** in high-to-excellent yields. **Table 2.2**, reveal that nitro, chloro, fluoro, bromo electron-withdrawing groups on benzaldehyde leads to excellent yields in shorter reaction time than electro donating groups like methoxy, methyl. Further under the same optimized conditions the reaction of different active methylene compounds like ethyl acetoacetate (**2b**), dimedone (**2c**) with various aldehydes (**1**) and 2-aminobenzimidazole (**3**) 1-(2-methyl-4-phenyl-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-3-yl)propan-1-one (**4m**), 1-(4-(4-methoxyphenyl)-2-methyl-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-3 yl)propan-1-one (**4n**), 1-(4-(4-chlorophenyl)-2-methyl-1,4-dihydrobenzo[4,5]imidazo[1,2 a]pyrimidin-3-yl)propan-1-one **(4o),** 1-(2-methyl-4-(4-nitrophenyl)-1,4 dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-3-yl)propan-1-one **(4p),** 3,3-dimethyl-12 phenyl-3,4,5,12-tetrahydrobenzo[4,5]imidazo[2,1-b]quinazolin-1(2H)-one **(4q),** 12-(4 methoxyphenyl)-3,3-dimethyl-3,4,5,12-tetrahydrobenzo[4,5]imidazo[2,1-b]quinazolin-1(2H)-one **(4r),** 3,3-dimethyl-12-(naphthalen-2-yl)-3,4,5,12tetrahydrobenzo[4,5]imidazo[2,1-b]quinazolin-1(2H)-one **(4s),** 3,3-dimethyl-12-(4 nitrophenyl)-3,4,5,12-tetrahydrobenzo[4,5]imidazo[2,1-b]quinazolin-1(2H)-one **(4t),** 12-(4 chorophenyl)-3,3-dimethyl-3,4,5,12-tetrahydrobenzo[4,5]imidazo[2,1-b]quinazolin-1(2H)-

Department of Chemistry IIT (BHU), Varanasi Page 54

one **(4u),** gave desired products in excellent yields but it took slightly longer reaction time than malanonitrile. Excellent chemoselectivity is an important aspect of this reaction it gave only (**4**) as the major product in very high yields and the other possible product (**5**) was not observed in this methodology (**Scheme 2.2**).

Table 2.2 Starch functionalized magnetite nanoparticles catalyzed the multicomponent synthesis of imidazopyrimidines (4a-u).

 Chapter 2

 Chapter 2

 Chapter 2

| $14\,$ | H_3CO \overline{O} CHO NH $\overline{\text{OCH}_3}$ | $\,8\,$ | 96 |
|--------|--|----------------|----|
| | 1 _c 4n | | |
| $15\,$ | CI, CHO O ·ŃH ĊI Ν | $\overline{6}$ | 97 |
| | 11 4 _o | | |
| $16\,$ | O_2N CHO NH NO ₂ Ν | $\overline{6}$ | 97 |
| | $\overline{\mathbf{H}}$ 4p | | |
| $17\,$ | O CHO ŃН N 1a 4q | $\overline{9}$ | 96 |

Department of Chemistry IIT (BHU), Varanasi Page 60

^a **Reaction conditions:** Benzaldehyde derivatives 1a-l (1.2 mmol), active methylenic compounds 2a-c (1.2), 2-amino benzimidazole 3 (1.0 mmol) and s -Fe₃O₄ (4 mg) in 5 mL water under ultrasound irradiation method, b isolated yield

Scheme 2.2 Chemoselective synthesis of 4

2.2.4 Reusability of *s***-Fe3O4 nanocatalyst**

The reusability of s -Fe₃O₄ nanocatalyst was also examined under the optimized reaction conditions up to 6 runs (**Figure 2.7**). The catalyst was separated by an external magnet after completion of the reaction, first washed with water and then methanol $(3x10mL)$, dried at 60 °C and used in next reaction. The collected catalyst could be reused numerous times in the succeeding runs without a significant loss of catalytic activities. Comparison of XRD pattern (**Figure 2.9**) and FT-IR spectra (**Figure 2.8**) of the fresh and recycled catalyst s -Fe₃O₄ has shown that the reaction conditions do not affect the structure and chemical nature of the catalyst.

Figure 2.7 Recyclability of catalyst upto 6 runs

Figure 2.8 XRD pattern of reused *s*-Fe3O⁴

Figure 2.9 FT-IR of reused *s*-Fe₃O₄

2.2.5 Proposed Mechanism

A proposed mechanism for the *s*-Fe3O4 catalyzed synthesis of imidazopyrimidine based on the product analysis is shown in **Figure 2.10**. In the presence s -Fe₃O₄ catalyst the carbonyl group of aldehyde get polarized and its electrophillicity that help the condensation with malanonitrile to from arylidenemalononitrile intermediate (**I**) by Knoevenagel reaction. In the next step, Michael addition by ring nitrogen atom of 2-aminobenzimidazole (**3**) to arylidenenitrile (**I**) followed by intermolecular cyclization (**II**) *in situ* and gives the product (**4**).

Figure 2.10 Plausible mechanism for *s*-Fe₃O₄ catalyzed synthesis of imidazopyrimidine

2.3 Experimental Section

2.3.1 General experimental procedure for the synthesis of imidazo pyrimidine derivatives (4a-u)

Aldehyde (1.2 mmol), active methylene compound (1.2 mmol), 2-aminobenzimidazole (1.0 mmol) and starch functionalized $Fe₃O₄$ (4 mg) were sonicated in water (5 mL) and progress of the reaction was monitored by TLC. The catalyst was collected by an external magnet, after completion of the reaction. The reaction mixture was extracted with ethyl acetate $(3\times10$ mL), washes with brine $(3\times10$ mL) and dried over sodium sulphate. The solvent was evaporated under vacuum and the solid obtained was purified by recrystallization.

2.4 Analytical data

2-Amino-4-phenyl-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carbonitrile (4a) Yield 98%; yellow powder; m.p. 234–236°C; **IR** (KBr) 3354, 3115, 2176 cm⁻¹; ¹H NMR $(500 \text{ MHz}, \text{DMSO-d}_6)$ δ (ppm): 8.57 (s, 1H, NH), 7.36-7.33 (t, 1H), 7.29-7.27(d, 2H), 7.23-7.22 (d, 1H), 7.13-7.10 (t, 1H), 7.02-6.99 (t, 1H), 6.79 (s, 2H), 5.21 (s, 1H); **¹³C NMR** (125 MHz, DMSO-d₆) δ (ppm): 151.39, 148.80, 143.13, 142.50, 128.89, 128.42, 127.60, 125.56, 123.12, 119.68, 118.85, 115.77, 112.02, 61.60, 52.89.

2-Amino-4-(o-tolyl)-1,4-dihydrobenzo[4,5]imidazolo[1,2-a]pyrimidine-3-carbonitrile (4b) Yield 95%; white powder; m.p. 235–236°C; **IR** (KBr) 3398, 3348, 2185 cm-1 ; ¹**H** NMR (500 MHz, DMSO-d₆) δ (ppm): 8.33 (s, 1H, NH), 7.66-7.64 (d, 2H), 7.23-7.17 (m, 3H), 7.13-7.10 (t, 2H), 7.02–6.99 (t, 1H), 6.78 (s, 2H), 5.48 (s, 1H), 2.41 (s, 3H); **¹³C NMR** (125 MHz, DMSO-d₆) δ (ppm): 151.56, 148.97, 143.22, 139.70, 134.63, 130.34, 128.90, 127.45, 126.11, 126.09, 122.95, 119.50, 118.48, 115.60, 111.97, 61.42, 49.95, 18.52.

2-Amino-4-(4-methoxyphenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3 carbonitrile (4c) Yield 93%; white powder; m.p. 265–266°C; **IR** (KBr) 3392, 3343, 2179 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.49 (s, 1H, NH), 7.63-7.62 (d, 1H), 7.22-7.19 (t, 3H), 7.12-7.09 (t, 1H), 7.01-6.98 (t, 1H), 6.91-6.90 (d, 2H), 6.78 (s, 2H), 5.14 (s, 1H), 3.71 (s, 3H); **¹³C NMR** (125 MHz, DMSO-d6) δ (ppm): 158.42, 151.27, 148.56, 143.13, 134.33, 128.81, 126.79, 122.80, 119.32, 118.70, 115.54, 113.53, 111.89, 61.82, 54.61, 52.27.

2-Amino-4-(naphthalen-1-yl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-

carbonitrile (4d) Yield 96%; white powder; m.p. 228–229°C; **IR** (KBr) 3390, 3340, 2183 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.66 (s, 1H, 1NH), 7.93-7.88 (m, 4H), 7.78 (s, 1H), 7.66-7.64 (d, 1H), 7.52-7.50 (m, 1H), 7.47-7.45 (m, 1H), 7.24-7.23 (d, 1H), 7.14- 7.10 (t, 1H), 7.02-6.99 (d, 1H), 6.86 (s, 2H), 5.41 (s, 1H); ¹³**C NMR** (125 MHz, DMSO-d₆) δ (ppm): 151.21, 148.73, 143.00, 139.59, 132.09, 128.81, 128.19, 127.39, 127.06, 126.01, 125.73, 124.06, 123.89, 122.84, 119.38, 118.67, 115.58, 114.52, 111.93, 61.31, 53.10.

2-Amino-4-(2-nitrophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-

carbonitrile (4e) Yield 96%; brown powder; m.p. 233–235 °C; **IR** (KBr) 3319, 2182, 1670, 1645, 1565 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.59 (s, 1H, NH), 7.62-7.61 (d, 1H), 7.56-7.55 (d, 1H), 7.25-7.22 (t, 2H), 7.13-7.10 (t, 1H), 7.02-6.99 (t, 2H), 6.85 (s, 2H), 5.23 (s, 1H); ¹³**C NMR** (125 MHz, DMSO-d₆) δ (ppm): 151.18, 148.88, 143.18,

141.47, 131.28, 128.84, 127.90, 123.12, 120.66, 119.69, 118.68, 115.79, 112.06, 60.99, 52.26.

2-Amino-4-(4-nitrophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-

carbonitrile (4f) Yield 98%; brown powder; m.p.> 300 °C; **IR** (KBr) 3329, 2180, 1677, 1640, 1560 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.75 (s, 1H), 8.25-8.23 (d, 2H), 7.64-7.62 (d, 1H), 7.56-7.55 (d, 2H), 7.26-7.24 (d, 1H), 7.14-7.11 (t, 1H), 7.03-7.00 (t,1H), 6.95 (s, 2H), 5.44 (s, 1H); **¹³C NMR** (125 MHz, DMSO-d6) δ (ppm): 150.97, 149.69, 148.99, 146.60, 128.76, 126.78, 123.63, 123.05, 119.63, 118.48, 115.77, 112.08, 60.15, 52.05.

2-Amino-4-(2-chlorophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-

carbonitrile (4g) Yield 95%; white powder; m.p. 232-234°C; **IR** (KBr) 3425, 3310, 2190 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.53 (s, 1H, NH), 7.66-7.65 (d, 1H), 7.48 (s, 1H), 7.34 (s, 1H), 7.25-7.23 (d, 1H), 7.15-7.12 (t, 1H), 7.04-7.01 (t, 1H), 6.88 (s, 2H), 5.64 (s, 1H); **¹³C NMR** (125 MHz, DMSO-d6) δ (ppm): 151.27, 149.14, 143.00, 138.86, 131.00, 129.33, 128.75, 128.03, 127.54, 123.08, 119.70,118.14,115.70, 112.07, 60.38, 50.45.

2-Amino-4-(3-chlorophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-

carbonitrile (4h) Yield 94%; white powder; m.p. 240–242 °C; **IR** (KBr) 3255, 2190, 1680, 1635, 1540 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.60 (s, 1H, NH), 7.84-7.83 (d, 1H), 7.80-7.79 (d, 1H), 7.63-7.55 (m, 1H), 7.38-7.34 (d, 1H), 7.25-7.24 (d, 2H), 7.13-7.10 (t, 1H), 7.02-6.99 (t, 1H), 6.88 (s, 2H), 5.24 (s, 1H); ¹³**C NMR** (125 MHz, DMSO-d₆) δ (ppm): 151.08, 148.74, 143.05, 141.73, 131.12, 130.92, 130.22, 128.75, 127.76, 122.89, 122.43, 120.47, 119.45, 118.55, 115.63, 111.97, 110.84, 60.88, 52.11.

2-Amino-4-(4-chlorophenyl)-1,4-dihydrobenzo[4,5]imidazolo[1,2-a]pyrimidine-3-

carbonitrile (4i) Yield 97%; yellow powder; m.p. 234-235°C; **IR** (KBr) 3443, 3315, 2185 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.59 (s, 1H, NH), 7.63-7.61 (d, 1H), 7.43-7.42 (d, 2H), 7.31-7.29 (d, 1H), 7.24-7.22 (d, 1H), 7.13-7.12 (d, 1H), 7.02-7.00 (d, 1H), 6.86 (s, 2H), 5.25 (s, 1H); **¹³C NMR** (125 MHz, DMSO-d6) δ (ppm): 151.11, 148.77, 143.07, 141.30, 131.97, 130.35,128.67, 128.24, 127.38, 122.94, 119.50, 118.58, 115.67, 111.99, 60.93, 51.78.

2-Amino-4-(2,3-dichlorophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-

carbonitrile (4j) Yield 96%; white powder; m.p. 245–246°C; **IR** (KBr) 3422, 3310, 3208, 2902, 2198 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.48 (s, 1H, NH), 7.65 – 7.63 (m, 1H), 7.45-7.43 (d, 1H), 7.38-7.36 (d, 1H), 7.25-7.24 (d, 1H), 7.15-7.12(t, 1H), 7.04- 7.01 (t, 1H), 6.88 (s, 2H), 5.63 (s, 1H); **¹³C NMR** (125 MHz, DMSO-d6) δ (ppm): 151.30, 149.40, 143.08, 137.88, 133.25, 132.26, 129.75, 128.94, 127.87,123.40, 120.05, 118.22, 115.97, 112.09, 59.42, 50.34.

2-Amino-4-(4-fluorophenyl)-1,4-dihydrobenzo[4,5]imidazolo[1,2-a]pyrimidine-3-

carbonitrile (4k) Yield 98%; yellow powder; m.p. 266–268 °C; **IR** (KBr) 3424, 3314, 3206, 3052, 2890 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.57 (s, 1H, NH), 7.647.62 (d, 1H), 7.34-7.31 (t, 1H), 7.24-7.17 (m, 3H), 7.13-7.10 (t, 1H) 7.02-7.00 (t, 1H), 6.84 (s, 2H), 5.25 (s, 1H); **¹³C NMR** (125 Hz, DMSO-d6) δ (ppm): 150.91, 149.11, 147.39, 144.58, 143.00, 132.31, 130.02, 128.74, 123.04, 122.42, 120.35, 120.35, 119.62, 118.51, 115.75, 112.05, 60.10, 51.84.

2-Amino-4-(4-bromophenyl)-1,4-dihydrobenzo[4,5]imidazolo[1,2-a]pyrimidine-3

carbonitrile (4l) Yield 97%; yellow powder; m.p.> 300 °C; **IR** (KBr) 3326, 2185, 1675, 1470, 1420 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 8.59 (s, 1H, NH), 7.62-7.61 (d, 1H), 7.56-7.55 (d, 2H), 7.25-7.22 (t, 2H), 7.13-7.10 (t, 1H), 7.02-6.99 (t, 1H), 6.85 (s, 2H), 5.23 (s, 1H); ¹³**C NMR** (125 MHz, DMSO-d₆) δ (ppm): 151.18, 148.88, 143.01, 141.79, 131.28, 128.84, 127.90, 123.12, 120.66, 119.69, 118.68, 115.79, 112.06, 60.06, 52.26.

1-(2-methyl-4-phenyl-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-3-yl)propan-1-

one (4m) Yield 95%; White powder; m.p 288-289°C; **IR** (KBr) 3025, 2975, 2940, 1695, 1580 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 10.79 (s, 1H), 7.35-7.33 (m, 3H), 7.27-7.23 (m, 3H), 7.19-7.16 (t, 1H), 7.05-7.02 (t, 1H), 6.96-6.93 (t, 1H), 6.41 (s, 1H), 4.02-3.97 (m, 2H), 2.45 (s, 3H), 1.14-1.12 (t, 3H); ¹³**C NMR** (125 MHz, DMSO-d₆) δ (ppm): 164.74, 146.12, 145.18, 141.27, 131.12, 128.00, 127.43, 126.70, 121.43, 119.85, 116.38, 109.46, 97.58, 59.23, 55.09, 18.20, 13.53.

1-(4-(4-methoxyphenyl)-2-methyl-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-3 yl)propan-1-one (4n) Yield 96%; White powder; m.p. 270-274°C; **IR** (KBr) 3050, 2980, 2958, 1615, 1575, 1260 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 10.79 (s, 1H), 7.34-7.33 (d, 1H), 7.28-7.25 (m, 3H), 7.05-7.02 (t, 1H), 6.96-6.93 (t, 1H), 6.81-6.79 (d, 2H), 6.37 (s, 1H), 4.02–4.00 (m, 2H), 3.57 (s, 3H), 2.45 (s, 3H), 1.16-1.13 (t, 3H); ¹³**C NMR** (125 MHz, DMSO-d₆) δ (ppm): 165.23, 164.74, 158.13, 145.82,145.62, 145.14, 145.12, 141.81, 133.66, 131.00, 127.79, 127.62, 121.19, 119.63, 119.58, 116.23, 113.24, 113.14, 109.38, 97.68, 97.60, 58.99, 54.21, 50.29, 18.13, 13.59.

1-(4-(4-chlorophenyl)-2-methyl-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-3-

yl)propan-1-one (4o) Yield 97%; White powder; m.p. 267-268°C; **IR** (KBr) 3061, 2935, 2840, 1620, 1573, 1270 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 10.86 (s, 1H), 7.39-7.36 (t, 3H), 7.34-7.32 (t, 3H), 7.26-7.24 (d, 1H), 7.06-7.03 (t, 1H), 6.97-6.94 (t, 1H), 6.45 (s, 1H), 4.03-4.02 (t, 2H), 2.46 (s, 3H), 1.16-1.13 (t, 3H); **¹³C NMR** (125 MHz, DMSO-d6) δ (ppm): 165.58, 147.33, 145.92, 142.77, 141.51, 132.80, 131.93, 129.53, 128.90, 122.38, 120.77, 117.36,110.34, 97.98, 59.93, 55.74, 19.16, 14.57.

1-(2-methyl-4-(4-nitrophenyl)-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidin-3-

yl)propan-1-one (4p) Yield 97%; White powder; m.p. 276-278°C; **IR** (KBr) 3055, 2940, 2837, 1675, 1570, 1260 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 10.97 (s, 1H), 8.14-8.12 (d, 2H), 7.66-7.64 (d, 2H), 7.37-7.35 (d, 1H), 7.27-7.26 (d, 1H), 7.06-7.03 (t, 1H), 6.97-6.64 (t, 1H), 6.60 (s, 1H), 4.03-4.01(m, 2H), 2.47 (s, 3H), 1.16-1.14(t, 3H); ¹³**C NMR** (125 MHz, DMSO-d₆) δ (ppm): 165.42, 148.51, 146.98, 146.42, 144.73, 141.73, 130.83, 128.01, 123.20, 121.53, 119.94, 116.47, 109.27, 96.29, 59.04, 54.73, 17.89, 13.54.

3,3-Dimethyl-12-phenyl-3,4,5,12-tetrahydrobenzo[4,5]imidazo[2,1-b]quinazolin-1(2H) one (4q) Yield 96%; White powder; m.p.> 300 °C; **IR** (KBr) 3431, 2890, 1640, 1622, 1588 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 11.12 (s, 1H, NH), 7.36-7.32 (d, 3H), 7.25 (s, 3H), 7.15 (s, 1H), 7.04 (s, 1H), 6.95 (s, 1H), 6.41 (s, 1H), 2.65-2.62 (d, 2H), 2.27-2.24 (d, 1H), 2.07-2.04 (d, 1H), 1.06 (s, 3H), 0.93 (s, 3H).

12-(4-methoxyphenyl)-3,3-dimethyl-3,4,5,12-tetrahydrobenzo[4,5]imidazo[2,1-

b]quinazolin-1(2H)-one (4r) Yield 98%; White powder; m.p.> 300 °C; **IR** (KBr) 3432, 2892, 1645, 1620, 1590 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 11.00 (s, 1H, NH), 8.17 (s, 1H), 7.33-732 (d, 1H), 7.23-7.21 (d, 2H), 7.17-7.15 (d, 1H), 7.03-7.00 (t, 1H), 6.93- 6.90 (t, 1H), 6.75-6.73 (s, 1H), 6.30 (s, 1H), 3.64 (s, 3H), 2.60-2.56 (d, 2H), 2.23-2.20 (d, 1H), 2.06-2.02 (d, 1H), 1.06 (s, 3H), 0.94 (s, 3H).

3,3-dimethyl-12-(naphthalen-2-yl)-3,4,5,12-tetrahydrobenzo[4,5]imidazo[2,1-

b]quinazolin-1(2H)-one (4s) Yield 95%; White powder; m.p.> 300 °C; **IR** (KBr) 3427, 2923, 2992, 1647, 1576 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 11.11 (s, 1H, NH), 8.15 (s, 1H), 7.96 (s, 1H), 7.84-7.83 (d, 1H), 7.74-7.69 (m, 1H), 7.44-7.29 (m, 4H), 7.19- 7.18 (d, 1H), 7.00-6.97 (t, 1H), 6.89-6.86 (t, 1H), 6.53 (s, 1H), 2.64-2.54 (m,2H), 2.24-2.21 (d, 1H), 2.05-2.01 (d, 1H), 1.07 (s, 3H), 0.93 (s, 3H).

3,3-dimethyl-12-(4-nitrophenyl)-3,4,5,12-tetrahydrobenzo[4,5]imidazo[2,1-

b]quinazolin-1(2H)-one (4t) Yield 98%; White powder; m.p.> 300 °C; **IR** (KBr) 3542, 3043, 1645, 1600, 1590 cm-**¹** ; **¹H NMR** (500 MHz, DMSO-d6) δ (ppm): 11.28 (s, 1H), 8.128.11 (d, 2H), 7.61-7.60 (d, 2H), 7.40-7.38 (d, 1H), 7.22-7.21 (d, 1H), 7.08-7.05 (t, 1H), 6.98-6.95 (t, 1H), 6.59 (s, 1H), 2.66-2.63 (t, 1H), 2.55-2.54 (t, 1H), 2.28-2.25 (d, 1H), 2.07- 2.04 (d, 1H), 1.05 (s, 3H), 0.90 (s, 3H).

12-(4-chorophenyl)-3,3-dimethyl-3,4,5,12-tetrahydrobenzo[4,5]imidazo[2,1-

b]quinazolin-1(2H)-one3 (4u) Yield 98%; White powder; m.p.> 300 °C; **IR** (KBr) 3442, 2956, 1646, 1617, 1590, 1569 cm⁻¹; ¹**H NMR** (500 MHz, DMSO-d₆) δ (ppm): 11.03 (s, 1H, NH), 8.18 (s, 1H), 7.34-7.30 (m, 2H), 7.22-7.19 (t, 2H), 7.14-7.12 (d, 1H), 7.03-7.00 (t, 1H), 6.93-6.90 (t, 1H), 2.60-2.57 (d, 1H), 2.39-2.36 (d, 1H), 2.24-2.20 (d, 1H), 2.07-2.04 (d, 1H), 1.07 (s, 3H), 0.94 (s, 3H).

2.5 Spectral data of product for few products

Department of Chemistry IIT (BHU), Varanasi Page 73

Figure 2.12 ¹H NMR $\&$ ¹³C NMR of 2-Amino-4-phenyl-1,4 dihydrobenzo[4,5]imidazo [1,2-a]pyrimidine-3-carbonitrile (4m)

2.6 References

Abedini, M., F. Shirini, M. Mousapour and O.G. Jolodar, "Poly (vinylpyrrolidonium) perchlorate catalyzed one-pot synthesis of tricyclic dihydropyrimidine derivatives," *Research on Chemical Intermediates*, **42(7)** (2016) 6221-6229.

Alajarin, R., J. J. Vaquero, J. Alvarez-Builla, M.F. de Casa-Juana, C. Sunkel, J.G. Priego, P. Gomez-Sal and R. Torres, "Imidazo [1, 5-a] pyrimidine and benzo [4, 5] imidazo [1, 2-a] pyrimidine derivatives as calcium antagonists," *Bioorganic & medicinal chemistry*, **2(5)** (1994) 323-329.

Badawey, E. and T. Kappe, "Benzimidazole condensed ring system. IX. Potential antineoplastics. New synthesis of some pyrido[1,2-α]benzimidazoles and related derivative," *European Journal of Medicinal Chemistry*, **30** (1995) 327-332.

Banerjee, B., "Recent developments on ultrasound-assisted one-pot multicomponent synthesis of biologically relevant heterocycles," *Ultrasonicssono chemistry*, **35** (2017) 15- 35.

Cappelletti, L., L. Vaghi, L. Rinaldi, L. Rotolo, G. Palmisano, G. Cravottoand A. Penoni, "One-pot sonochemical synthesis of ferrocenyl derivatives via a three-component reaction in aqueous media," *Ultrasonicssono chemistry*, **27** (2015) 30-36.

Gawande, M.B., A. Velhinho, I.D. Nogueira, C.A.A. Ghumman, O.M.N.D. Teodoroand P.S., Branco, "A facile synthesis of cysteine–ferrite magnetic nanoparticles for application in multicomponent reactions—a sustainable protocol," *RSC Advances*, **2(15)** (2012) 6144- 6149.

Gupta, A., R. Jamatia and A.K. Pal, "Ferrite-supported glutathione: an efficient, green nano-organocatalyst for the synthesis of pyran derivatives," *New Journal of Chemistry*, **39(7)** (2015) 5636-5642.

Hemmati, B., S. Javanshir and Z. Dolatkhah, "Hybrid magnetic Irish moss/Fe₃O₄ as a nanobiocatalyst for synthesis of imidazopyrimidine derivatives," *RSC advances* **6(56)** (2016) 50431-50436.

Hu, L., Z. Zhan, M. Lei and L. Hu, "Facile and green method for the synthesis of 4-amino-1, 2-dihydrobenzo [4, 5] imidazo [1, 2-a] pyrimidine-3-carbonitriles catalysed by ammonium acetate," *Journal of Chemical Research*, **36(12)** (2012) 738-739.

Kaur, N., K. Kaur, T. Raj, G. Kaur, A. Singh, T. Aree, S.J. Park, T.J. Kim, N. Singh and D.O Jang, "One-pot synthesis of tricyclic dihydropyrimidine derivatives and their biological evaluation," *Tetrahedron*, **71(2)** (2015) 332-337.

Klutchko, S. R., J. M. Hamby, D. H. Boschelli, Z. Wu, A.J. Kraker, A. M. Amar, B. G. Hartl, C. Shen, W. D. Klohs and R. W. Steinkampf, "2-Substituted aminopyrido [2, 3-d] pyrimidin-7 (8 H)-ones. Structure−activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity," *Journal of medicinal chemistry,* **41** (1998) 17 3276-3292.

Kalita, S.J., D.C. Deka and H. Mecadon, "Organocatalytic domino Knöevenagel–Michael reaction in water for the regioselective synthesis of benzo [4, 5] imidazo [1, 2-a]

Department of Chemistry IIT (BHU), Varanasi Page 76

pyrimidines and pyrido [2, 3-d] pyrimidin-2-amines," *RSC advances*, **6(94)** (2016) 91320- 91324.

Khazaei, A., M.A. Zolfigol, F. Karimitabar, I. Nikokar and A.R. Moosavi-Zare, "N, 2- Dibromo-6-chloro-3, 4-dihydro-2 H-benzo [e][1, 2, 4] thiadiazine-7-sulfonamide 1, 1 dioxide: an efficient and homogeneous catalyst for one-pot synthesis of 4 H-pyran, pyranopyrazole and pyrazolo [1, 2-b] phthalazine derivatives under aqueous media," *RSC Advances*, **5(87)** (2015) 71402-71412.

Komykhov, S.A., I.G. Tkachenko, V.I. Musatov, M.V. Diachkov, V.A. Chebanov and S.M. Desenko, "Multicomponent synthesis in water of 7-unsubstituted 4, 7-dihydro-1, 2, 4 triazolo [1, 5-a] pyrimidines and their antimicrobial and antifungal activity," *Arkivoc*, (2016) 277-287.

Le Corre, L., A.L. Girard, J. Aubertin, F. Radvanyi, C. Benoist-Lasselin, A. Jonquoy, E. Mugniery, L. Legeai-Mallet and Y. Le Merrer, "Synthesis and biological evaluation of a triazole-based library of pyrido [2, 3-d] pyrimidines as FGFR3 tyrosine kinase inhibitors," *Organic &biomolecular chemistry*, **8(9)** (2010) 2164-2173.

Maleki, A., N. Ghamari and M. Kamalzare, "Chitosan-supported $Fe₃O₄$ nanoparticles: a magnetically recyclable heterogeneous nanocatalyst for the syntheses of multifunctional benzimidazoles and benzodiazepines," *RSC advance*s, **4** (2014) 9416-9423.

Meshram, H.M., A.S. Kumar, G.S. Kumar, A. Swetha, B.C. Reddy and P. Ramesh, "Boric acid promoted an efficient and practical synthesis of fused pyrimidines in aqueous media," *Der PharmaChem*, **4** (2012) 956-960.

Mout, R., D.F. Moyano, S. Rana and V.M. Rotello, "Surface functionalization of nanoparticles for nanomedicine," *Chemical Society Reviews*, **41(7)** (2012) 2539-2544.

 Nagarapu, L., H.K. Gaikwad, J. D. Palem, R. Venkatesh, R. Bantu and B. Sridhar, "Convenient approach for the one-pot, three-component synthesis of triheterocyclic 4 Hpyrimido [2, 1-b] benzothiazole derivatives using TBAHS," *Synthetic Communications*, **43(1)** (2013) 93-104.

 Neochoritis, C. G., T. Zarganes-Tzitzikas, C. A. Tsoleridis, J. Stephanidou-Stephanatou, C. A. Kontogiorgis, D. J. Hadjipavlou-Litina and T. Choli-Papadopoulou, "One-pot microwave assisted synthesis under green chemistry conditions, antioxidant screening, and cytotoxicity assessments of benzimidazole Schiff bases and pyrimido [1, 2-a] benzimidazol-3 (4H)-ones," *European Journal of Medicinal Chemistry*, **46(1)** (2011) 297- 306.

 Noori, Y., K. Akhbari, A. Phuruangrat and F. Costantino, "Studies the effects of ultrasonic irradiation and dielectric constants of solvents on formation of lead (II) supramolecular polymer; new precursors for synthesis of lead (II) oxide nanoparticles," *Ultrasonicssonochemistry*, **35** (2017) 36-44.

 Reddy, M.V., J. Oh and Y.T. Jeong, *"p*-Toluenesulfonic acid-catalyzed one-pot synthesis of 2-amino-4-substituted-1, 4-dihydrobenzo [4, 5] imidazolo [1, 2-a] pyrimidine-3-carbonitriles under neat conditions," *Comptes Rendus Chimie*, **17(5)** (2014) 484-489.

 Rajarathinam, B., K. Kumaravel and G. Vasuki, "Green chemistry oriented multicomponent strategy to hybrid heterocycles," *RSC advances*, **6(77)** (2016) 73848-73852.

Radatz, C.S., R.B. Silva, G. Perin, E.J. Lenardão, R.G. Jacob and D. Alves, "Catalyst-free synthesis of benzodiazepines and benzimidazoles using glycerol as recyclable solvent," *Tetrahedron letters*, **52(32)** (2011) 4132-4136.

Shaabani, A., A. Rahmati and S. Naderi, "A novel one-pot three-component reaction: Synthesis of triheterocyclic 4H-pyrimido [2, 1-b] benzazoles ring systems," *Bioorganic & medicinal chemistry letters*, **15(24)** (2005) 5553-5557.

Sheibani, H. and M. Babaie, "Three-component synthesis of 4-amino-2-aryl-2H-pyrimido- [1, 2-b][1, 3] benzazole-3-carbonitriles and 4H-pyrimido-[2, 1-b][1, 3] benzazoles in the presence of magnesium oxide and 12-tungstophosphoric acid as catalysts," *Russian Chemical Bulletin*, **62(10)** (2013) 2202-2208.

Shaterian, H.R., N. Fahimi and K. Azizi, "New applications of phosphoric acid supported on alumina $(H_3PO_4 - Al_2O_3)$ as a reusable heterogeneous catalyst for preparation of 2, 3dihydroquinazoline-4 (1H)-ones, 2H-indazolo [2, 1-b] phthalazinetriones, and benzo [4, 5] imidazo [1, 2-a] pyrimidines," *Research on Chemical Intermediates,* **40(5)** (2014) 1879- 1898.

Shirini, F., M. Seddighi and O. Goli-Jolodar, "Facile and efficient synthesis of pyrimido [1, 2-a] benzimidazole and tetrahydrobenzimidazo [2, 1-b] quinazolin-1 (2H)-one derivatives using Brönsted acidic ionic liquid supported on rice husk ash $(RHA$ -[pmim] $HSO₄)$," *Journal of the Iranian Chemical Society*, **13(11)** (2016) 2013-2018.

Survase, D., B. Bandgar and V. Helavi, "Polyethylene glycol-promoted synthesis of pyrimido [1, 2-a] benzimidazole and pyrano [2,3-c] pyrazole derivatives in water," *Synthetic Communications*, **47(7)** (2017) 680-687.

Singh, S., M. Saquib, M. Singh, J. Tiwari, F. Tufail, J. Singh and J. Singh, "A catalyst free, multicomponent-tandem, facile synthesis of pyrido [2,3-d] pyrimidines using glycerol as a recyclable promoting medium," *New Journal of Chemistry*, **40(1)** (2016) 63-67.

Subbiah, R., M. Veerapandian and S K. Yun, "Nanoparticles: functionalization and multifunctional applications in biomedical sciences," *Current medicinal chemistry*, **17(36)** (2010) 4559-4577.

Singh, P.N., D. Tiwary and I. Sinha,"Starch-functionalized magnetite nanoparticles for hexavalent chromium removal from aqueous solutions," *Desalination and Water Treatment*, **57(27)** (2016) 12608-12619.

Tabassum, S., S. Govindaraju and M.A. Pasha, "Ultrasound mediated, iodine catalyzed green synthesis of novel 2-amino-3-cyano-4H-pyran derivatives," *Ultrasonics sonochemistry*, **24** (2015) 1-7.

Tamaddon, F. and M. Alizadeh, "A four-component synthesis of dihydropyrano [2, 3-c] pyrazoles in a new water-based worm-like micellar medium," *Tetrahedron Letters*, **55(26)** (2014) 3588-3591.

Velasco, J., E. Pérez-Mayoral, V. Calvino-Casilda, A.J. López-Peinado, M.A. Bañares and E. Soriano, "ImidazoliumSulfonates as Environmental-Friendly Catalytic Systems for the Synthesis of Biologically Active 2-Amino-4 H-chromenes: Mechanistic Insights," *The Journal of Physical Chemistry B*, **119(36)** (2015) 12042-12049.

Wahe, H., P. F. Asobo, R. A. Cherkasov, A. E. Nkengfack, G. N. Folefoc, Z. T. Fomum and D. Doepp, "Heterocycles of biological importance. Part 6. The formation of novel biologically active pyrimido [1, 2-a] benzimid-azoles from electron deficient alkynes and 2-aminobenzimidazoles," *Arkivoc*, (**xiv**) (2003) 170-177.

Warekar, P. P., P.T. Patil, K. T. Patil, D. K. Jamale, G. B. Kolekar and P.V. Anbhule, " cofriendly synthesis and biological evaluation of 4-(4-nitro-phenyl)-2-phenyl-1, 4 dihydro-benzo [4, 5] imidazo [1, 2-a] pyrimidine-3-carboxylic acid ethyl ester derivatives as an antitubercular agents," *Synthetic Communications*, **46(24)** (2016) 2022-2030.

Wu, L., F. Yan and C. Yang, "Silica sulfuric acid promoted one-pot synthesis of benzo [4, 5] imidazo [1, 2-a] pyrimidine derivatives under solvent-free conditions," *Bulletin of the Chemical Society of Ethiopia*, **24(3)** (2010) 417-423.

Yao, C., S. Lei, C. Wang, T. Li, C. Yu, X. Wang and S. Tu, "Three‐component synthesis of 4‐aryl‐1H‐pyrimido [1, 2‐a] benzimidazole derivatives in ionic liquid," *Journal of Heterocyclic Chemistry*, **47(1)** (2010) 26-32.

Yao, C. S., S. Lei, C. H. Wang, C. X. Yu, Q. Q. Shao and S. J. Tu, "One‐pot Three‐component Solvent‐free Synthesis of Benzo [4,5] imidazo [1,2‐a] pyrimidine Derivatives Catalyzed by Sulfamic Acid" *Chinese Journal of Chemistry*, **26(11)** (2008) 2107-2111.

Zhao, H. and S. V. Malhotra, "Applications of ionic liquids in organic synthesis," *Aldrichimica Acta*. **35** (2002) 75-83.

Zou, Y., Y. Hu, H. Liu and D. Shi, "Rapid and efficient ultrasound-assisted method for the combinatorial synthesis of spiro [indoline-3, 4′-pyrano [2, 3-c] pyrazole] derivatives," *ACS combinatorial science*, **14(1)** (2012) 38-43.